Search results for: Margherita Neri
Filter search results
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…for Global Development | Ideas to Action (cgdev.org) Neri, M., Hampson, G., Henshall, C. and Towse, A. 2019. HTA and Payment Mechanisms for New Drugs to Tackle AMR. OHE Grant-Funded…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…Health Care. 2021;37(S1):19-19. doi:10.1017/S0266462321001124 Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18(1):31. doi:10.1186/s12962-020-00223-x Cole A, Neri M, Cookson G….
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
13 October 2025
…the national economy by averting productivity losses and keeping the workforce healthy and in work.” Notes to Editors Please reference the report as: El-Banhawi H., Hodgson S., Neri…
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
…Related Research Lorgelly, P.K. and Neri, M. 2018. Survivorship Burden for Individuals, Households and Society: Estimates and Methodology. Journal of Cancer Policy, 15(B), pp.113-7. DOI Devlin, N., Lorgelly, P. 2017….
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…the healthcare system and political factors, which can have an effect. Download the full report here. Citation Berdud, M., Garau, M., Neri, M., O’Neill, P., Sampson, C….
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…A., Lorgelly, P., and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper 18/04. RePEc. Lorgelly, P.K. and Neri, M., 2018. Survivorship…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
…Pricing in the US and Five Major European Countries . Consulting Report, Office of Health Economics. Neri, M., Towse, A., and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…of Risperidone. OHE Research Paper 19/xx, London: Office of Health Economics. Available at: https://www.ohe.org/publications/case-risperidone-assessing-life-cycle-value-second-generation-antipsychotics-sweden-and Related research Berdud, M., Garau, M., Neri, M., O’Neill, P., Sampson, C. and Towse, A….
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…when more expensive ones may be appropriate. ‘Volume-delinked’ payments may instead represent a longer-term solution because these schemes encourage better adherence to stewardship. Neri, M., Hampson, G., Henshall, C….